83 results about "Diabetic cardiomyopathy" patented technology

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

The present invention relates to a method of making novel dipeptidyl peptidase-IV ("DPP-IV') inhibitor compounds useful for treating, inter alia, diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, metabolic syndrome (Syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of making 3,3,4,4-tetrafluoropyrrolidine, a starting material utilized in the afore-mentioned method for preparing DPP-IV compounds.

Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems, (iv) plaque rupture of atheromatous lesions of major blood vessels such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the fermoral arteries and the popliteal arteries, (v) diabetes or the complications of diabetes.

The invention provides compounds of Formula (I)

or prodrugs thereof, or pharmaceutically acceptable salts of said compounds or prodrugs, or solvates of said compounds, prodrugs or salts, wherein A, N, X and R¹ are as defined herein; pharmaceutical compositions thereof; and methods of using the pharmaceutical compositions for the treatment of diseases, including Type 2 diabetes, Type 1 diabetes, impaired glucose tolerance, hyperglycemia, metabolic syndrome (syndrome X and/or insulin resistance syndrome), glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, short stature due to growth hormone deficiency, infertility due to polycystic ovary syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome; short bowel syndrome; and the prevention of disease progression in Type 2 diabetes.

Hibernating myocardium is characterized by viable myocardium with impaired function due to localized reduced perfusion. Hibernating myocytes retain cellular integrity, but cannot sustain high-energy requirements of contraction. High plasma levels of catecholamines, such as norepinepherine, are believed to be predictive of mortality from hibernating myocardium. Likewise, high levels of catecholamines lead to cardiomyopathy in patients with diabetes. GLP-1 reduces plasma norepinepherine levels, and it thus is useful in a method of treating hibernating myocardium or diabetic cardiomyopathy.

The present invention discloses an application of pentacyclic triterpenoid saponin represented by formulas (I) to (XIII) for the preparation of a medicine for preventing or treating AMPK-mediated diseases including fatty liver disease, inflammatory bowel disease, respiratory disease, diabetic complications and polycystic kidney disease. The compounds of formula (I) to (XIII) are especially usefulfor nonalcoholic simple fatty liver, nonalcoholic steatohepatitis, non-alcoholic steatohepatitis-induced cirrhosis, ulcerative colitis, Crohn's disease, chronic obstructive Pulmonary diseases, asthma,idiopathic pulmonary fibrosis, cystic fibrosis, allergic rhinitis, diabetic nephropathy, diabetic cardiomyopathy, diabetic ulcers, and autosomal dominant polycystic kidney disease. A pharmaceutical composition for preventing and treating the AMPK-mediated diseases of the present invention comprises a therapeutically effective amount of the compounds of the formula (I) to (XIII) or a pharmaceutically acceptable salt or a solvate thereof as an active ingredient and a pharmaceutically acceptable excipient.

A method of treating a living mammal having diabetic cardiomyopathy comprises administering an effective amount of an inhibitor to the mammal performing a shotgun lipidomics analysis on the mammal and determining that the treatment was successful when and if serum or tissue biopsy cardiolipin levels are increased and/or lysocardiolipin levels are decreased.

The present invention provides methods of treating diabetic cardiomyopathy, the methods comprising administering to a patient having or at risk of having diabetic cardiomyopathy a therapeutically effective amount of a glycogen phosphorylase inhibitor. The present invention also provides methods of treating diabetic cardiomyopathy, the methods comprising administering to a patient having 1) diabetes and 2) having cardiovascular disease, ischemic heart disease, congestive heart failure, congestive heart failure but not having coronary arteriosclerosis, hypertension, diastolic blood pressure abnormalities, microvascular diabetic complications, abnormal left ventricular function, myocardial fibrosis, abnormal cardiac function, pulmonary congestion, small vessel disease, small vessel disease without atherosclerotic cardiovascular disease or luminal narrowing, coagulopathy, cardiac contusion, or having had or at risk of having a myocardial infarction a therapeutically effective amount of a glycogen phosphorylase inhibitor.

The invention discloses a medicine composition for preventing and/or treating diabetes and complication of diabetes. The medicine composition is prepared from Chinese herbaceous peony and cassia bark in a weight ratio of (10-1) to 1. The medicine composition comprises the following effective components in parts by weight: 50-150 parts of a pinane monoterpene glycoside compound in Chinese herbaceous peony, and 1-5 parts of a cinnamic acid/aldehyde compound. The medicine composition not only has a good and stable blood sugar reduction and weight loss function, but also can effectively prevent and treat multiple diabetes complications, such as fatty liver, diabetic cardiomyopathy, diabetes peripheral neuritis, diabetes eye diseases and diabetic nephropathy. The composition is low in toxicity, small in side effect, low in cost and safe to use.

This invention relates to methods of treating or preventing type 2 diabetes, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic microangiopathy, diabetic macroangiopathy, diabetic ischemia reperfusion injury, diabetic cardiac ischemia reperfusion injury and/or insulin resistance syndrome (IRS) in mammals, particularly in humans, by administering a sodium-hydrogen exchanger type 1 (NHE-1) inhibitor or a pharmaceutical composition containing such an inhibitor. This invention also relates to combinations comprising NHE-1 inhibitors and a second pharmaceutical agent, said combinations being useful in treating type 2 diabetes, IRS, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic ischemia reperfusion injury, diabetic cardiac ischemia reperfusion injury, diabetic microangiopathy and/or diabetic macroangiopathy.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, asthma, and the like.

The invention relates to application of an oral hypoglycemic peptide. The application is used for preparing a medicine or a medicine composition for treating or preventing diabetes complicated with cardiovascular diseases. The oral hypoglycemic peptide is polypeptide OHP2. The polypeptide can effectively improve myocardial hypertrophy and fibrosis damage caused by the diabetes, reduce the contentof related myocardial enzymes, adjust the lipid metabolism level and improve myocardial cell oxidative stress and mitochondrial damage, so that the effect of protecting the heart is achieved; and therefore, the polypeptide can be used as a candidate molecule for treating or preventing the diabetes complicated with the cardiovascular diseases (especially diabetic cardiomyopathy), and has a good application prospect.

The invention discloses a construction method of a diabetic cardiomyopathy animal model. An SD (Sprague Dawley) rat under high-sugar and high-fat feeding is subjected to multiple abdominal injection with STZ (streptozocin); after the diabetics diagnosis standard is reached, subcutaneous injection with isoprenaline is performed; after 2 weeks of continued feeding, left ventricular cannulation and three-lead electrocardiogram test of ventricular hemodynamic parameters and electrocardiogram parameters shows that the rat experiences cardiac dysfunction; heart weight index and left ventricular index show that the rat experiences evident ventricular hypertrophy; biochemical analysis on rat blood shows that the rat has evident myocardial damage; HE (hematoxylin-eosin) pathological staining satisfies pathological changes in diabetic cardiomyopathy; Masson collagen staining satisfies myocardial connective tissue proliferation of diabetic cardiomyopathy. The construction method has the advantages of good operational simplicity, short construction time, low mortality in construction phase, high construction success rate and the like, and the pathological process of myocardial damage due to human type 2 diabetes mellitus can be well simulated.

The invention discloses a new application of methazolamide, and particularly relates to a new application of methazolamide in preparation of a medicine for treating type 1 diabetic cardiomyopathy. In the research, the inventor of the application finds that the methazolamide can reduce the blood sugar of the type 1 diabetic cardiomyopathy, improve the heart morphological structure abnormality and cardiac contraction and diastolic dysfunction of the type 1 diabetic cardiomyopathy, can improve myocardial hypertrophy caused by high glucose, and has a good treatment effect on the type 1 diabetic cardiomyopathy. The invention provides a new drug choice for the treatment of type 1 diabetic cardiomyopathy.

The invention relates to application of 1-deoxynojirimycin in the treatment of diabetic cardiomyopathy and liver injury. 1-Deoxynojirimycin is a known potent alpha-glucosidase inhibitor. The applicable field of 1-deoxynojirimycin is widened herein; the use of 1-deoxynojirimycin or its pharmaceutically acceptable salts in the treatment and/or prevention of diabetic cardiomyopathy and liver injury is provided for the first time; experiments show that 1-deoxynojirimycin plays a positive role in myocardial protection aspects, such as lowering cardiac oxidative stress level of a diabetic patient, inhibiting cardiovascular endothelial cell proliferation of the diabetic patient, and inhibiting myocardial fiber proliferation of the diabetic patient; it is expected to develop 1-deoxynojirimycin into drugs to treat diabetic cardiomyopathy, thereby filling the blank of the prior art.

The invention relates to the technical field of natural medicine, and particularly discloses an effective exocarpium part and an application of the effective exocarpium part to preparing of medicine for treating diabetic cardiomyopathy. A preparing method of the effective exocarpium part includes the steps that S1, extraction is carried out through an organic solvent for exocarpium, and organic solvent extract is obtained; S2, the organic solvent extract is fed to a macroreticular resin column, elution is carried out through ethyl alcohol with the volume fraction of 10% to 30% for purification, then elution is carried out through ethyl alcohol with the volume fraction of 50% to 70%, and the ethyl alcohol elution part of 50% to 70% is collected; S3, effective ingredients of the ethyl alcohol elution part of 50% to 70% obtained in the step S2 are gathered in a silica gelcolumn chromatography mode, and the effective exocarpium part is obtained. By means of the effective exocarpium part, the content of rat-myocardium NF-kappaB protein can be remarkably reduced, and the effective exocarpium part can be used for treating diabetic cardiomyopathy.